Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

23.8%

5 terminated/withdrawn out of 21 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

7 trials in Phase 3/4

Results Transparency

70%

7 of 10 completed trials have results

Key Signals

2 recruiting7 with results

Enrollment Performance

Analytics

Phase 1

8(38.1%)

Phase 3

5(23.8%)

Phase 2

5(23.8%)

Phase 4

2(9.5%)

Early Phase 1

1(4.8%)

21Total

Phase 1(8)

Phase 3(5)

Phase 2(5)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT05712707Phase 1Active Not Recruiting

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

Role: collaborator

NCT05025605Phase 1Recruiting

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Role: lead

NCT05558982Phase 2Active Not Recruiting

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT06041646Phase 4Completed

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Role: lead

NCT05271552Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

Role: lead

NCT06335407Phase 1Recruiting

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Role: collaborator

NCT03910660Phase 1Completed

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Role: lead

NCT05658510Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Role: lead

NCT07116694Phase 2Active Not Recruiting

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Role: lead

NCT04382170Phase 2Withdrawn

Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy

Role: collaborator

NCT05665088Phase 3Terminated

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Role: lead

NCT04470050Phase 1Completed

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

Role: lead

NCT04827056Phase 1Completed

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Role: collaborator

NCT06093451Phase 4Unknown

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Role: collaborator

NCT04251910Phase 1Completed

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

Role: lead

NCT04276883Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

Role: lead

NCT05276830Phase 2Terminated

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

Role: lead

NCT04268303Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Role: lead

NCT04010305Phase 1Completed

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Role: lead

NCT05313386Phase 2Withdrawn

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

Role: lead